- Home
- MLYS vs VLGEA Comparison
MLYS vs VLGEA Comparison
Compare MLYS & VLGEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- VLGEA
- Stock Information
- Founded
- MLYS 2019
- VLGEA 1937
- Country
- MLYS United States
- VLGEA United States
- Employees
- MLYS N/A
- VLGEA N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- VLGEA Food Chains
- Sector
- MLYS Health Care
- VLGEA Consumer Staples
- Exchange
- MLYS Nasdaq
- VLGEA Nasdaq
- Market Cap
- MLYS 526.1M
- VLGEA 504.7M
- IPO Year
- MLYS 2023
- VLGEA N/A
- Fundamental
- Price
- MLYS $10.86
- VLGEA $34.38
- Analyst Decision
- MLYS Strong Buy
- VLGEA
- Analyst Count
- MLYS 2
- VLGEA 0
- Target Price
- MLYS $30.00
- VLGEA N/A
- AVG Volume (30 Days)
- MLYS 263.5K
- VLGEA 30.6K
- Earning Date
- MLYS 03-20-2025
- VLGEA 03-04-2025
- Dividend Yield
- MLYS N/A
- VLGEA 2.94%
- EPS Growth
- MLYS N/A
- VLGEA 2.47
- EPS
- MLYS N/A
- VLGEA 3.48
- Revenue
- MLYS N/A
- VLGEA $2,257,909,000.00
- Revenue This Year
- MLYS N/A
- VLGEA N/A
- Revenue Next Year
- MLYS N/A
- VLGEA N/A
- P/E Ratio
- MLYS N/A
- VLGEA $9.80
- Revenue Growth
- MLYS N/A
- VLGEA 3.42
- 52 Week Low
- MLYS $8.58
- VLGEA $24.57
- 52 Week High
- MLYS $16.91
- VLGEA $34.69
- Technical
- Relative Strength Index (RSI)
- MLYS 51.57
- VLGEA 64.72
- Support Level
- MLYS $9.81
- VLGEA $33.13
- Resistance Level
- MLYS $10.79
- VLGEA $34.69
- Average True Range (ATR)
- MLYS 0.62
- VLGEA 0.72
- MACD
- MLYS 0.15
- VLGEA 0.17
- Stochastic Oscillator
- MLYS 100.00
- VLGEA 89.27
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.